Prostate neuroendocrine neoplasm
MONDO:0002477A neoplasm with neuroendocrine differentiation that arises from the prostate gland. This category includes carcinoid tumors and small cell carcinomas.
Also known as: neuroendocrine neoplasm of prostate, neuroendocrine neoplasm of prostate gland, neuroendocrine neoplasm of the prostate, neuroendocrine tumour of the prostate, prostate gland NET, prostate gland neuroendocrine neoplasm, prostate gland neuroendocrine tumor, prostate gland neuroendocrine tumor, well differentiated, low or intermediate grade
1473 clinical trials for this condition and its sub-types, 20 tagged with Prostate neuroendocrine neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Prostate neuroendocrine neoplasm
-
Prostate small cell carcinoma 9 trials
-
New drug BL-M14D1 targets tough cancers in early human trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…
Phase 1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New radioactive drug targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, 225Ac-ETN029, in 116 adults with advanced DLL3-positive cancers like small cell lung cancer or neuroendocrine tumors. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Pa…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Engineered immune cells take on tough cancers in first human trial
Disease control Recruiting nowThis early-phase trial tests a new treatment called ML261 for people with advanced small cell lung cancer or certain neuroendocrine cancers that have not responded to standard treatments. ML261 is made from a patient's own immune cells, which are modified in a lab to better recog…
Phase 1 • Sponsor: Moonlight Bio, Inc • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New antibody drug targets Hard-to-Treat neuroendocrine cancers
Disease control Recruiting nowThis study tests a new drug, peluntamig (PT217), in people with advanced neuroendocrine cancers like small cell lung cancer. The drug is designed to attach to two proteins (DLL3 and CD47) found on cancer cells, potentially helping the immune system attack them. The trial will fir…
Phase 1/2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Radioactive drug targets tough prostate cancer
Disease control Recruiting nowThis study tests a radioactive drug called lutetium Lu 177 dotatate in men with advanced prostate cancer that has neuroendocrine features. The drug seeks out and kills cancer cells that have a specific protein on their surface. The goal is to see if it can shrink tumors. About 35…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New radioactive drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new drug that delivers radiation directly to cancer cells carrying a specific protein called GRPR. The study includes 48 adults with advanced cancers like prostate, breast, lung, or colon cancer that have not responded to standard treatments. The ma…
Phase 1 • Sponsor: Orano Med Theranostics, SAS • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Experimental drug tarlatamab takes on rare, Tough-to-Treat cancer
Disease control Recruiting nowThis phase 2 trial is testing a drug called tarlatamab in 60 adults with advanced extrapulmonary neuroendocrine carcinoma, a rare cancer that has come back after standard chemotherapy. Tarlatamab works by helping the body's immune cells find and attack cancer cells. The main goal…
Phase 2 • Sponsor: Inkeun Park • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug duo takes on tough prostate cancers
Disease control Recruiting nowThis phase 2 trial is testing a combination of two drugs—sacituzumab tirumotecan and tagitanlimab—in people with aggressive variant or neuroendocrine prostate cancer that has progressed after prior treatments. The study aims to see if the combo can shrink tumors and delay disease…
Phase 2 • Sponsor: Tianjin Medical University Second Hospital • Aim: Disease control
Last updated Jun 26, 2026 18:44 UTC